dc.contributor.author |
Sequeiros, Tamara |
dc.contributor.author |
Rigau, Marina |
dc.contributor.author |
Chiva, Cristina |
dc.contributor.author |
Montes, Melania |
dc.contributor.author |
Garcia-Grau, Iolanda |
dc.contributor.author |
García, Marta |
dc.contributor.author |
Diaz, Sherley |
dc.contributor.author |
Celma, Ana |
dc.contributor.author |
Bijnsdorp, Irene |
dc.contributor.author |
Campos, Alex |
dc.contributor.author |
Di Mauro, Primiano |
dc.contributor.author |
Borrós, Salvador |
dc.contributor.author |
Reventós, Jaume |
dc.contributor.author |
Doll, Andreas |
dc.contributor.author |
Paciucci, Rosanna |
dc.contributor.author |
Pegtel, Michiel |
dc.contributor.author |
de Torres, Inés |
dc.contributor.author |
Sabidó, Eduard |
dc.contributor.author |
Morote Robles, Juan |
dc.contributor.author |
Olivan, M. |
dc.contributor.author |
Universitat Autònoma de Barcelona |
dc.date |
2016 |
dc.identifier |
https://ddd.uab.cat/record/186043 |
dc.identifier |
urn:10.18632/oncotarget.13634 |
dc.identifier |
urn:oai:ddd.uab.cat:186043 |
dc.identifier |
urn:pmid:27903962 |
dc.identifier |
urn:pmcid:PMC5354884 |
dc.identifier |
urn:pmc-uid:5354884 |
dc.identifier |
urn:articleid:19492553v8p4960 |
dc.identifier |
urn:oai:egreta.uab.cat:publications/4987eadc-9455-4552-b65e-e3278212df3f |
dc.identifier |
urn:scopus_id:85012035008 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:5354884 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
Instituto de Salud Carlos III PI11-02486 |
dc.relation |
Instituto de Salud Carlos III CD12-00475 |
dc.relation |
Instituto de Salud Carlos III RD12-0036-0035 |
dc.relation |
Instituto de Salud Carlos III PT13-0001 |
dc.relation |
Ministerio de Economía y Competitividad SEV-2012-0208 |
dc.relation |
Agència de Gestió d'Ajuts Universitaris i de Recerca 2014SGR678 |
dc.relation |
Oncotarget ; Vol. 8 (november 2016), p. 4960-4976 |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by/4.0/ |
dc.subject |
Prostate cancer |
dc.subject |
Biomarkers |
dc.subject |
Urine |
dc.subject |
Extracellular vesicles |
dc.subject |
Diagnosis |
dc.title |
Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer |
dc.type |
Article |
dc.description.abstract |
Altres ajuts: The study was supported by grants AECC-JB-2013-02 of Asociación Española Contra el Cáncer, 7th Framework Programe, IRSES (PROTBIOFLUID −269285) - Belgium, pre-doctoral fellowship of Vall d'Hebron Research Institute (VHIR) and cofinanced by the European Regional Development Fund(ERDF). |
dc.description.abstract |
Rapid and reliable diagnosis of prostate cancer (PCa) is highly desirable as current used methods lack specificity. In addition, identification of PCa biomarkers that can classify patients into high- and low-risk groups for disease progression at early stage will improve treatment decision-making. Here, we describe a set of protein-combination panels in urinary extracellular vesicles (EVs), defined by targeted proteomics and immunoblotting techniques that improve early non-invasive detection and stratification of PCa patients.We report a two-protein combination in urinary EVs that classifies benign and PCa patients (ADSV-TGM4), and a combination of five proteins able to significantly distinguish between high- and low-grade PCa patients (CD63-GLPK5-SPHM-PSA-PAPP). Proteins composing the panels were validated by immunohistochemistry assays in tissue microarrays (TMAs) confirming a strong link between the urinary EVs proteome and alterations in PCa tissues. Moreover, ADSV and TGM4 abundance yielded a high diagnostic potential in tissue and promising TGM4 prognostic power. These results suggest that the proteins identified in urinary EVs distinguishing high- and low grade PCa are a reflection of histological changes that may be a consequence of their functional involvement in PCa development. In conclusion, our study resulted in the identification of protein-combination panels present in urinary EVs that exhibit high sensitivity and specificity for PCa detection and patient stratification. Moreover, our study highlights the potential of targeted proteomic approaches-such as selected reaction monitoring (SRM)-as diagnostic assay for liquid biopsies via urinary EVs to improve diagnosis and prognosis of suspected PCa patients. |